ETNHX Mutual Fund Forecast & Price Targets

Compare

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ETNHX Analyst Rating

Moderate Buy

53 Buy

14 Hold

0 Sell

Based on the consensus analyst ratings on 67 stocks held in ETNHX.

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ETNHX Analyst Price Target

Average Price Target

$60.10

Based on 67 Wall Street analysts offering 12 month price targets to Eventide Healthcare & Life Sciences Fd Cl N holdings in the last 3 months. The average price target is $60.10 with a high forecast of $79.50 and a low forecast of $40.96. The average price target represents a 93.01% change from the last price of $31.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"$28","41":"$41","54":"$54","67":"$67","80":"$80"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":79.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$79.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.961,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,41,54,67,80],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n              \n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.18,34.89692307692307,38.613846153846154,42.33076923076923,46.04769230769231,49.76461538461538,53.48153846153846,57.19846153846154,60.91538461538461,64.63230769230769,68.34923076923076,72.06615384615384,75.78307692307692,{"y":79.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.18,33.404923076923076,35.62984615384615,37.85476923076923,40.079692307692305,42.30461538461538,44.529538461538465,46.75446153846154,48.97938461538462,51.204307692307694,53.42923076923077,55.65415384615385,57.87907692307692,{"y":60.104,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.18,31.932384615384613,32.68476923076923,33.43715384615385,34.18953846153846,34.941923076923075,35.69430769230769,36.44669230769231,37.19907692307692,37.95146153846154,38.70384615384615,39.45623076923077,40.208615384615385,{"y":40.961,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34.11,"date":1714521600000,"info":"<div>Price: <b>$34<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":33.55,"date":1717372800000,"info":"<div>Price: <b>$34<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":33.43,"date":1719792000000,"info":"<div>Price: <b>$33<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":35.94,"date":1722470400000,"info":"<div>Price: <b>$36<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":35.48,"date":1725321600000,"info":"<div>Price: <b>$35<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":35.18,"date":1727740800000,"info":"<div>Price: <b>$35<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":35.65,"date":1730419200000,"info":"<div>Price: <b>$36<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":35.59,"date":1733097600000,"info":"<div>Price: <b>$36<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.99,"date":1735776000000,"info":"<div>Price: <b>$33<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.8,"date":1738540800000,"info":"<div>Price: <b>$35<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.3,"date":1740960000000,"info":"<div>Price: <b>$32<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":29.11,"date":1743465600000,"info":"<div>Price: <b>$29<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31.18,"date":1746057600000,"info":"<div>Price: <b>$31<b/></div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$79.50

Average Price Target$60.10

Lowest Price Target$40.96

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

ETNHX Stocks With Highest Upside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

SLN

Silence Therapeutics Plc

5 Buy

0 Hold

1 Sell

Moderate Buy

$35.80

xxxxxxxxxxxxxxxxxxxxxxxxxxx

INZY

Inozyme Pharma, Inc.

8 Buy

0 Hold

0 Sell

Strong Buy

$13.29

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ANNX

Annexon Biosciences, Inc.

7 Buy

0 Hold

0 Sell

Strong Buy

$14.20

xxxxxxxxxxxxxxxxxxxxxxxxxxx

NKTR

Nektar Therapeutics

6 Buy

1 Hold

1 Sell

Moderate Buy

$4.92

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ZNTL

Zentalis Pharmaceuticals Inc

5 Buy

4 Hold

0 Sell

Moderate Buy

$7.25

ETNHX Stocks With Highest Downside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

IRTC

Irhythm Technologies

11 Buy

0 Hold

0 Sell

Strong Buy

$139.10

xxxxxxxxxxxxxxxxxxxxxxxxxxx

TMDX

Transmedics Group

4 Buy

3 Hold

0 Sell

Moderate Buy

$98.00

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ARGX

Argenx

19 Buy

2 Hold

0 Sell

Strong Buy

$752.71

xxxxxxxxxxxxxxxxxxxxxxxxxxx

TGTX

TG Therapeutics

5 Buy

0 Hold

1 Sell

Moderate Buy

$43.00

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ALNY

Alnylam Pharmaceuticals

19 Buy

4 Hold

0 Sell

Strong Buy

$317.29

ETNHX Mutual Fund FAQ

What is ETNHX’s average 12-month price target, according to analysts?

Based on analyst ratings, Eventide Healthcare & Life Sciences Fd Cl N’s 12-month average price target is 60.10.

What is ETNHX’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for ETNHX, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ETNHX a Buy, Sell or Hold?

Eventide Healthcare & Life Sciences Fd Cl N has a consensus rating of Moderate Buy which is based on 53 buy ratings, 14 hold ratings and 0 sell ratings.

What is Eventide Healthcare & Life Sciences Fd Cl N’s price target?

The average price target for Eventide Healthcare & Life Sciences Fd Cl N is 60.10. This is based on 67 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $79.50 ,the lowest forecast is $40.96. The average price target represents N/A Increase from the current price of N/A.

What do analysts say about Eventide Healthcare & Life Sciences Fd Cl N?

Eventide Healthcare & Life Sciences Fd Cl N’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 67 Wall Streets Analysts.

How can I buy shares of ETNHX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing